Olanzapine

Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (K_i=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (K_i=11 to 31 nM), muscarinic M1-5 (K_i=1.9-25 nM), and adrenergic α1 receptor (K_i=19 nM). Olanzapine is an atypical antipsychotic^[1][2]. In Vitro: Olanzapine binds weakly to GABAA, Benzodiazepine (BZD), and β-adrenergic receptors (K_i>10 μM) ^[1][2].
Olanzapine induces autophagy in human SH-SY5Y neuronal cell line^[3].
Olanzapine (1-100 μM for 144 h under serum starvation) results in a marked anti-proliferative effect in glioblastoma cell lines as well as glioma stem-like cells^[4].
Olanzapine also enhances Temozolomide’s anti-tumor activity in glioblastoma cell lines^[4].
Olanzapine induces apoptosis and necrosis in glioblastoma cell lines^[4].
In Vivo: Olanzapine (0.75, 1.5 and 3 mg/kg) evaluates body weight and periuterine fat mass, as well as insulin, non-esterified fatty acids, triglycerides, and glucose levels in mice^[5]